Europe Fermented Ingredients Market Analysis by Mordor Intelligence
The Europe Fermented ingredients market size is estimated at USD 10.21 billion in 2025, and is expected to reach USD 15.67 billion by 2030, at a CAGR of 8.95% during the forecast period (2025-2030). This acceleration reflects a structural shift in how European manufacturers source functional molecules, driven by pharmaceutical demand for bio-based active pharmaceutical ingredients and consumer preference for recognizable ingredient labels. The European Commission's 2024 biotech and biomanufacturing strategy positions the region to capture a larger share of the global biotechnology market, where Europe currently holds a substantial share[1]Source: European Commission," biotech and biomanufacturing", research-and-innovation.ec.europa.eu. Structural demand for bio-based actives in pharmaceuticals, rising clean-label expectations in foods, and the European Commission’s biotech strategy collectively accelerate adoption across the Europe fermented ingredients market. German and Dutch fermentation hubs supply commodity amino acids and organic acids at scale, while France and Italy channel fresh investment into high-purity APIs and precision strains.
Key Report Takeaways
- By ingredient type, amino acids led with 44.02% of the Europe fermented ingredients market share in 2024, while probiotics and starter cultures are forecast to grow at a 9.03% CAGR through 2030.
- By form, dry and powder formats accounted for 72.45% of the Europe fermented ingredients market size in 2024; liquid formats are projected to expand at a 9.55% CAGR to 2030.
- By application, food and beverages captured 45.67% of the Europe fermented ingredients market in 2024, whereas pharmaceuticals are set to advance at a 10.45% CAGR during the forecast period.
- By geography, Germany held 28.11% revenue share of the Europe fermented ingredients market in 2024, and France is anticipated to record the fastest growth at a 10.23% CAGR up to 2030.
Europe Fermented Ingredients Market Trends and Insights
Drivers Impact Analysis
| Driver | (~) % Impact on CAGR Forecast | Geographic Relevance | Impact Timeline |
|---|---|---|---|
| Growing interest in functional foods with health benefits | +1.2% | Germany, France, the Netherlands, with spillover to Spain and Italy | Medium term (2-4 years) |
| Increasing use of fermented acids and enzymes in the food and beverages sector | +1.5% | Pan-European, concentrated in Germany, France, UK | Short term (≤ 2 years) |
| Clean-label requirement driving fermentation ingredient adoption | +1.3% | Germany, France, the Netherlands, the UK, Nordic countries | Medium term (2-4 years) |
| Growing pharmaceutical demand for bio-based fermentation APIs | +1.8% | Germany, France, Italy, the Netherlands | Long term (≥ 4 years) |
| Expanding incorporation of probiotics in personal care products | +0.8% | France, Germany, the UK, with emerging adoption in Spain | Medium term (2-4 years) |
| Improved shelf life using fermentation-derived preservatives | +0.7% | Pan-European, particularly in packaged food hubs | Short term (≤ 2 years) |
| Source: Mordor Intelligence | |||
Growing Pharmaceutical Demand for Bio-Based Fermentation APIs
Europe's drive to reshore pharmaceutical supply chains is redirecting capital toward fermentation-based active pharmaceutical ingredient production, a strategic response to the vulnerabilities exposed during COVID-19 when Asian API imports faltered. EUROAPI operates two large-scale fermentation sites in France and Italy with a combined capacity of nearly 6,000 cubic meters and full cGMP compliance, positioning the company to serve both innovator and generic drug manufacturers. Lonza's mammalian and microbial fermentation platforms in Switzerland and adjacent European facilities supply biologics and small-molecule APIs, leveraging decades of process development expertise. The European Medicines Agency's emphasis on supply security and the EU's pharmaceutical strategy, which targets 40% of critical API production within the bloc by 2030, are accelerating investments in fermentation infrastructure. Evonik's BioMilk platform, which uses yeast to biosynthesize tropane alkaloids traditionally extracted from plants, demonstrates how fermentation can de-risk supply chains dependent on agricultural inputs.
Clean-Label Requirement Driving Fermentation Ingredient Adoption
Consumer demand for ingredient transparency is compelling food manufacturers to replace synthetic additives with fermentation-derived alternatives that carry familiar names and natural origin claims. The European Food Safety Authority authorized buffered vinegar (E 267) in 2023 for use as a preservative in various food categories, validating fermentation-based preservation systems that extend shelf life without triggering clean-label concerns[2]Source: European Union, "European Food Safety Authority", efsa.europa.eu. Kerry Group's BioKerry platform integrates fermentation-derived enzymes, cultures, and flavor compounds to help customers reformulate products with shorter ingredient lists while maintaining sensory profiles. Corbion's lactic acid and lactates, produced via fermentation in the Netherlands, serve as multifunctional ingredients that acidify, preserve, and enhance texture without the stigma attached to chemical preservatives. Regulatory frameworks such as the EU's food enzyme regulation (EC) No 1332/2008 require rigorous safety assessments, yet once approved, fermentation enzymes like subtilisin and chymosin benefit from broad application permissions across dairy, baking, and beverage categories.
Increasing Use of Fermented Acids and Enzymes in Food and Beverages Sector
Fermented organic acids and industrial enzymes have become indispensable processing aids in European food and beverage manufacturing, enabling cost reduction, yield improvement, and novel product formats. Citric acid, produced via Aspergillus niger fermentation, functions as an acidulant and chelating agent in beverages, confectionery, and dairy, with Cargill and other producers operating large-scale facilities that convert molasses or glucose into multi-thousand-ton annual outputs. Enzymes such as amylases, proteases, and lipases accelerate starch conversion in brewing, protein hydrolysis in cheese making, and fat modification in bakery applications, reducing processing time and energy consumption. EFSA issued positive opinions in 2024 for glutaminase from Bacillus subtilis and bacillolysin from Bacillus amyloliquefaciens, expanding the toolkit available to food technologists. Novonesis, formed from the Novozymes-Chr. Hansen merger commands a leading position in food enzymes with a portfolio spanning dairy, baking, brewing, and protein processing, supported by EUR 3.6 billion in combined revenue and extensive application laboratories.
Growing Interest in Functional Foods with Health Benefits
European consumers increasingly prioritize foods that deliver tangible health benefits beyond basic nutrition, creating demand for fermentation ingredients that support gut health, immune function, and metabolic wellness. The DOMINO project, a multi-country research initiative involving 4,917 adults across 7 European nations, documented consumer perceptions of fermented foods and identified key drivers of acceptance, including perceived naturalness and digestive benefits. Probiotics such as Lactobacillus and Bifidobacterium strains are incorporated into yogurts, dietary supplements, and functional beverages, with DuPont's HOWARU range offering clinically documented strains for digestive and immune support. Prebiotics, which are often produced via enzymatic conversion of plant substrates, are gaining traction as formulators seek to substantiate health claims under EFSA's stringent evaluation framework. The European Food Safety Authority maintains a Qualified Presumption of Safety (QPS) list that streamlines approval for well-characterized microbial strains, reducing regulatory burden for probiotic developers.
Restraints Impact Analysis
| Restraint | (~) % Impact on CAGR Forecast | Geographic Relevance | Impact Timeline |
|---|---|---|---|
| High specialized fermentation infrastructure costs hinder growth | -0.9% | Germany, France, the Netherlands, Italy | Long term (≥ 4 years) |
| Complex regulatory approval processes delay product launches | -0.8% | Pan-European, particularly affecting novel strains and applications | Medium term (2-4 years) |
| Competition from non-fermented functional ingredient alternatives | -0.5% | Germany, France, UK, Spain | Short term (≤ 2 years) |
| Fragmented starter culture supply chain complexity | -0.4% | Pan-European, with acute pressure in specialty dairy segments | Medium term (2-4 years) |
| Source: Mordor Intelligence | |||
High Specialized Fermentation Infrastructure Costs Hinder Growth
Capital requirements for fermentation facilities impose significant barriers to entry and constrain capacity expansion, particularly for smaller players lacking access to patient capital or established cash flows. Greenfield fermentation plants equipped with stainless-steel bioreactors, aseptic filling lines, and downstream purification systems, all meeting cGMP standards for pharmaceutical or food-grade production, typically require upfront investments exceeding USD 50 million, with lead times stretching 3 to 5 years from design to commissioning. Evonik's six European fermentation sites, collectively housing over 4,000 cubic meters of capacity, represent decades of accumulated investment and process optimization that few competitors can replicate. Energy costs for sterilization, agitation, and temperature control further burden operating economics, with European natural gas prices in 2024 remaining elevated relative to pre-2022 levels.
Complex Regulatory Approval Processes Delay Product Launches
Navigating the European Union's regulatory landscape for fermentation ingredients demands extensive dossier preparation, safety testing, and agency review, delaying commercialization and increasing development costs. The Novel Food Regulation (EU) 2015/2283 requires comprehensive safety assessments for ingredients derived from novel strains or processes, with EFSA review timelines often extending 18 to 24 months from submission to authorization. Food enzyme applications under Regulation (EC) No 1332/2008 similarly require detailed characterization of production organisms, enzyme purity, and intended use conditions, with EFSA issuing scientific opinions that can take 12 to 18 months. The Substances of Human Origin (SoHO) Regulation 2024/1938, which entered into force in 2024, introduces additional oversight for certain biological materials, potentially affecting fermentation-derived ingredients from human-associated microbiota. Divergent national interpretations of EU frameworks further complicate market entry, as member states retain discretion over certain implementation details.
Segment Analysis
By Ingredient Type: Amino Acids Lead, Probiotics Accelerate
Amino Acids captured 44.02% of the europe fermented ingredients market in 2024, reflecting decades of entrenched demand from animal feed compounders and pharmaceutical synthesizers who rely on lysine, methionine, threonine, and tryptophan to optimize livestock growth and drug intermediates. Ajinomoto's EUR 150 million investment in Belgium during 2024 to expand specialty amino acid production underscores the strategic importance of this segment, as the company seeks to serve both nutrition and pharmaceutical customers with high-purity grades. Evonik's methionine production, a critical amino acid for poultry and swine diets, leverages fermentation and chemical synthesis routes to deliver consistent quality at scale. Probiotics and Starter Cultures, however, are forecast to grow fastest at 9.03% CAGR from 2025 to 2030, driven by expanding applications in functional foods, dietary supplements, and fermented dairy products. The January 2024 merger of Novozymes and Chr. Hansen into Novonesis consolidated two probiotic powerhouses, creating a platform with extensive strain libraries and application expertise across human and animal health.
Organic Acids, including citric, lactic, and acetic acids, serve as acidulants, preservatives, and pH regulators across food, beverage, and industrial applications, with Corbion's lactic acid production in the Netherlands exemplifying large-scale fermentation economics. Vitamins, particularly B-complex vitamins like riboflavin (B2), cobalamin (B12), and biotin, are produced via fermentation by DSM-Firmenich and BASF, leveraging microbial biosynthesis to achieve cost and sustainability advantages over chemical routes. Industrial Enzymes, proteases, amylases, lipases, cellulases, enable process intensification in baking, brewing, detergents, and biofuels, with Novonesis commanding a leading position through its combined enzyme portfolio. Polymers, such as polylactic acid (PLA) and polyhydroxyalkanoates (PHA), represent emerging segments where fermentation-derived monomers offer biodegradable alternatives to petrochemical plastics, though commercial scale remains limited. The Others category encompasses specialty molecules like biosurfactants, flavor compounds, and pigments, where fermentation enables access to complex structures difficult to synthesize chemically.
Note: Segment shares of all individual segments available upon report purchase
By Form: Dry Powder Dominates, Liquid Gains Traction
Dry and Powder forms held 72.45% of the European fermented ingredients market in 2024, a dominance rooted in superior shelf stability, reduced transportation costs, and ease of handling in downstream formulation processes. Spray drying, freeze drying, and drum drying technologies convert fermentation broths into free-flowing powders that retain enzymatic activity, probiotic viability, or chemical potency over extended storage periods, critical for global supply chains and just-in-time manufacturing. Lallemand's yeast and bacteria products, widely used in baking and brewing, are predominantly supplied in dry formats that tolerate ambient storage and simplify dosing. Kerry Group's enzyme and culture offerings similarly leverage dry formulations to serve diverse food manufacturers across Europe.
Liquid forms, however, are projected to expand at 9.55% CAGR from 2025 to 2030, driven by continuous fermentation systems that deliver fresh, high-titer broths directly to adjacent processing lines, eliminating drying costs and preserving heat-sensitive bioactives. Corbion's lactic acid is often supplied in liquid concentrate, enabling efficient integration into beverage and dairy production. Liquid probiotics and enzymes are gaining traction in applications where immediate activity is prioritized over long-term storage, such as on-site inoculation in cheese making or real-time enzyme addition in brewing. The shift toward liquid formats reflects broader trends in process integration and sustainability, as eliminating drying steps reduces energy consumption and carbon footprint, aligning with Europe's Green Deal objectives.
By Application: Food Dominates, Pharmaceuticals Surge
Food and Beverages applications commanded 45.67% of the European fermented ingredients market in 2024, reflecting the sector's massive consumption of organic acids, enzymes, probiotics, and vitamins across dairy, baking, brewing, confectionery, and beverage production. Enzymes such as amylases and proteases accelerate starch conversion and protein hydrolysis, reducing processing time and improving yield, while probiotics and starter cultures define product identity in yogurt, cheese, and fermented beverages. Organic acids like citric and lactic acid regulate pH, enhance flavor, and extend shelf life, with Corbion and Cargill operating large-scale production facilities. The European Food Safety Authority's 2024 opinions on glutaminase and bacillolysin expanded the enzyme toolkit available to food technologists, enabling novel applications in plant-based protein processing and flavor development. Pharmaceuticals, however, are forecast to grow fastest at 10.45% CAGR from 2025 to 2030, propelled by Europe's strategic push to reshore API production and reduce dependence on Asian suppliers.
Animal Feed applications consume large volumes of amino acids, lysine, methionine, threonine, and enzymes like phytase and xylanase to optimize livestock nutrition and reduce environmental impact through improved feed conversion ratios. Cosmetics and Personal Care represent a niche but growing segment, with probiotics and fermentation-derived bioactives incorporated into skincare formulations targeting microbiome balance and anti-aging benefits. S-Biomedic's LiveSkin Probiotic, approved for acne treatment in the EUR 4.4 billion European acne market, demonstrates the therapeutic potential of fermentation ingredients in dermatology. Other Applications encompass industrial chemicals, textiles, and specialty materials, where fermentation-derived molecules offer sustainability advantages over petrochemical routes.
Geography Analysis
Germany held 28.11% of the European fermented ingredients market in 2024, anchored by a robust biotechnology infrastructure, pharmaceutical manufacturing clusters, and established fermentation capacity across amino acids, enzymes, and vitamins. Evonik's six European sites, including multiple facilities in Germany, collectively house over 4,000 cubic meters of fermentation capacity and serve pharmaceutical, nutrition, and industrial customers. BASF's vitamin production, also concentrated in Germany, leverages fermentation for riboflavin and other B-complex vitamins, integrating with the company's broader chemical portfolio.
France is projected to grow fastest at 10.23% CAGR from 2025 to 2030, driven by government support for biotechnology innovation, precision fermentation ventures, and pharmaceutical API reshoring. Roquette, a French family-owned company with EUR 4.3 billion in revenue, operates fermentation capabilities for specialty ingredients and plant-based proteins. The Netherlands benefits from a concentrated biotech cluster, with Corbion's lactic acid production and DSM-Firmenich's vitamin and culture operations anchoring the sector. Wageningen University's fermentation research programs further strengthen the innovation ecosystem, supplying talent and technology to industry partners. Spain and Italy are emerging as attractive locations for fermentation investments, supported by competitive labor costs, renewable energy availability, and proximity to Mediterranean food and beverage markets. EUROAPI's Italian site complements its French operations, providing geographic redundancy and access to southern European customers.
The United Kingdom, despite Brexit-related regulatory divergence, retains significant fermentation capacity in enzymes and specialty ingredients, with Tate & Lyle operating food ingredient facilities. Russia's fermentation sector remains constrained by geopolitical tensions and limited access to Western technology, though domestic producers continue to serve local food and pharmaceutical markets. The rest of Europe, encompassing Nordic countries, Eastern Europe, and smaller Western European nations, collectively contributes to regional capacity through specialized producers and contract fermentation operators, with regulatory harmonization under EU frameworks facilitating cross-border trade and investment.
Competitive Landscape
The European fermented ingredients market exhibits moderate fragmentation, reflecting a competitive landscape where multinational ingredient conglomerates, regional specialists, and contract fermentation operators coexist across diverse application niches. The January 2024 merger of Novozymes and Chr. Hansen into Novonesis, creating a EUR 3.6 billion revenue entity, exemplifies consolidation pressure as players seek scale in enzyme and probiotic portfolios to cross-sell into pharmaceutical, food, and animal nutrition channels. DSM-Firmenich, formed in May 2023 with combined revenue of EUR 12.6 billion, similarly leverages fermentation platforms spanning vitamins, cultures, and bioactives to serve multiple end markets and geographies.
Strategic moves center on vertical integration, with companies like Corbion and Evonik controlling fermentation capacity, downstream processing, and application development to capture margin across the value chain. Opportunities persist in precision fermentation for alternative proteins, where regulatory clarity around novel food approvals remains uneven across member states, and in biopolymer production, where commercial-scale economics have yet to be demonstrated. Smaller entrants and academic spin-outs target niche segments such as biosurfactants, specialty enzymes, and rare amino acids, leveraging strain engineering and process optimization to compete on performance rather than cost.
Technology adoption patterns reveal a bifurcation between commodity fermentation, where cost leadership and scale drive competitive advantage, and specialty fermentation, where intellectual property around strains, processes, and applications creates defensible positions. Evonik's BioMilk platform, which uses yeast to biosynthesize tropane alkaloids, demonstrates how fermentation can de-risk supply chains dependent on agricultural inputs and create proprietary positions through process patents. Ajinomoto's EUR 150 million investment in Belgium during 2024 to expand specialty amino acid capacity reflects a strategy of moving up the value curve toward pharmaceutical-grade molecules with higher margins and switching costs. Contract fermentation operators, such as Lonza's CDMO services, enable smaller pharmaceutical and biotech companies to access fermentation capacity without capital investment, creating a parallel competitive dynamic where flexibility and regulatory compliance substitute for scale.
Europe Fermented Ingredients Industry Leaders
-
Cargill, Incorporated
-
Döhler GmbH
-
DuPont
-
BASF SE
-
DSM‑Firmenich
- *Disclaimer: Major Players sorted in no particular order
Recent Industry Developments
- December 2025: REWE Group, a leading European retailer, officially joined Food Fermentation Europe, signaling broader industry collaboration to advance fermentation technologies and sustainable protein solutions in the EU.
- September 2025: Precision fermentation company Nourish Ingredients launched a global commercial hub in Leiden, Netherlands, to scale its animal-free fats and fermentation-derived ingredient innovation, with the facility becoming operational by 2026.
Europe Fermented Ingredients Market Report Scope
Fermented ingredients are foods or beverages transformed by desirable microbial growth (bacteria, yeasts, molds) and their enzymatic action. The Europe fermented ingredients market is segmented by ingredient type, form, application, and geography. By ingredient type, the market is segmented into amino acids, organic acids, polymers, vitamins, industrial enzymes, and more. By form, the market is segmented into liquid and dry/powder. By application, the market is segmented into food and beverages, feed, animal feed, pharmaceuticals, cosmetics, personal care, and other applications. By geography, the market is segmented into the United Kingdom, France, Germany, and more. The market forecasts are provided in terms of value (USD).
| Amino Acids |
| Organic Acids |
| Vitamins |
| Industrial Enzymes |
| Probiotics / Starter Cultures |
| Polymers |
| Antibiotics |
| Others |
| Liquid |
| Dry / Powder |
| Food and Beverages |
| Pharmaceuticals |
| Animal Feed |
| Cosmetics and Personal Care |
| Biofuel |
| Other Applications |
| United Kingdom |
| Germany |
| France |
| Spain |
| Italy |
| Russia |
| Netherlands |
| Rest of Europe |
| By Ingredient Type | Amino Acids |
| Organic Acids | |
| Vitamins | |
| Industrial Enzymes | |
| Probiotics / Starter Cultures | |
| Polymers | |
| Antibiotics | |
| Others | |
| By Form | Liquid |
| Dry / Powder | |
| By Application | Food and Beverages |
| Pharmaceuticals | |
| Animal Feed | |
| Cosmetics and Personal Care | |
| Biofuel | |
| Other Applications | |
| By Geography | United Kingdom |
| Germany | |
| France | |
| Spain | |
| Italy | |
| Russia | |
| Netherlands | |
| Rest of Europe |
Key Questions Answered in the Report
How large is the Europe fermented ingredients market in 2025?
The Europe fermented ingredients market size stands at USD 10.21 billion in 2025.
What CAGR is expected for fermented ingredients in Europe through 2030?
Revenue is forecast to rise at an 8.95% CAGR, reaching USD 15.67 billion by 2030.
Which ingredient type leads revenue today?
Amino acids command 44.02% of revenue, reflecting entrenched demand in feed and pharma.
Page last updated on: